bluuebunny/crossref_metadata_2025 huggingface dataset:
Supplementary Figure 1b from Biomarker Analyses of Clinical Outcomes in Patients with Advanced Hepatocellular Carcinoma Treated with Sorafenib with or without Erlotinib in the SEARCH Trial
Authors: Zhu Andrew X. , Kang Yoon-Koo , Rosmorduc Olivier , Evans T.R. Jeffry , Santoro Armando , Ross Paul , Gane Edward , Vogel Arndt , Jeffers Michael , Meinhardt Gerold , Peña Carol E.A.
Published: April 2023

Supplementary Figure 1. Kaplan-Meier survival curves of treatment effect on TTP in patients with low (left panel) and high (right panel) baseline levels of (A) epiregulin (max chi interaction P value = 0.193), (B) VEGF-A (max chi interaction P value = 0.153), (C) HGF (max chi interaction P value = 0.157), and (D) PDGF (max chi interaction P value = 0.167). All biomarkers were dichotomized using the max chi optimized cutoff. BL=baseline; Erlot=erlotinib; HGF=hepatocyte growth factor; PDGF=platelet-derived growth factor; Pla=placebo; Sor=sorafenib; TTP=time to progression; VEGF=vascular endothelial growth factor.
Supplementary Dataset 1 from Matrix Screen Identifies Synergistic Combination of PARP Inhibitors and Nicotinamide Phosphoribosyltransferase (NAMPT) Inhibitors in Ewing Sarcoma
Authors: Heske Christine M. , Davis Mindy I. , Baumgart Joshua T. , Wilson Kelli , Gormally Michael V. , Chen Lu , Zhang Xiaohu , Ceribelli Michele , Duveau Damien Y. , Guha Rajarshi , Ferrer Marc , Arnaldez Fernanda I. , Ji Jiuping , Tran Huong-Lan , Zhang Yiping , Mendoza Arnulfo , Helman Lee J. , Thomas Craig J.
Published: April 2023

Single-agent outcomes
Raw data 1 from Evaluation of Salivary Exosomal Chimeric GOLM1-NAA35 RNA as a Potential Biomarker in Esophageal Carcinoma
Authors: Lin Yusheng , Dong Hongmei , Deng Weilun , Lin Wan , Li Kai , Xiong Xiao , Guo Yi , Zhou Fuyou , Ma Changchun , Chen Yuping , Ren Hongzheng , Yang Haijun , Dai Ningtao , Ma Lang , Meltzer Stephen J. , Yeung Sai-Ching J. , Zhang Hao
Published: April 2023

Raw data 1-Supplementary Zip including supplementary tables with the qRT-PCR data from the patient cohorts with the amplification profile data (tissue archive and discovery cohort)
Supplementary Figure S6 from PD-L1 Is a Therapeutic Target of the Bromodomain Inhibitor JQ1 and, Combined with HLA Class I, a Promising Prognostic Biomarker in Neuroblastoma
Authors: Melaiu Ombretta , Mina Marco , Chierici Marco , Boldrini Renata , Jurman Giuseppe , Romania Paolo , D'Alicandro Valerio , Benedetti Maria C. , Castellano Aurora , Liu Tao , Furlanello Cesare , Locatelli Franco , Fruci Doriana
Published: April 2023

This figure includes Kaplan-Meier curves of RFS (A, C and E) and EFS (B, D and F) according to the combined PD-L1+ and HLA-I+ tumor-cell densities with the MYCN amplification status (A and B), INSS stage (C and D) or age at diagnosis (E and F).
Supplemental Table 5 from A Combination CDK4/6 and IGF1R Inhibitor Strategy for Ewing Sarcoma
Authors: Guenther Lillian M. , Dharia Neekesh V. , Ross Linda , Conway Amy , Robichaud Amanda L. , Catlett Jerrel L. , Wechsler Caroline S. , Frank Elizabeth S. , Goodale Amy , Church Alanna J. , Tseng Yuen-Yi , Guha Rajarshi , McKnight Crystal G. , Janeway Katherine A. , Boehm Jesse S. , Mora Jaume , Davis Mindy I. , Alexe Gabriela , Piccioni Federica , Stegmaier Kimberly
Published: April 2023

Related to Figure 5
Supplemental Table 2 from A Combination CDK4/6 and IGF1R Inhibitor Strategy for Ewing Sarcoma
Authors: Guenther Lillian M. , Dharia Neekesh V. , Ross Linda , Conway Amy , Robichaud Amanda L. , Catlett Jerrel L. , Wechsler Caroline S. , Frank Elizabeth S. , Goodale Amy , Church Alanna J. , Tseng Yuen-Yi , Guha Rajarshi , McKnight Crystal G. , Janeway Katherine A. , Boehm Jesse S. , Mora Jaume , Davis Mindy I. , Alexe Gabriela , Piccioni Federica , Stegmaier Kimberly
Published: April 2023

Related to Figure 1
Supplemental Figure 5 from A Combination CDK4/6 and IGF1R Inhibitor Strategy for Ewing Sarcoma
Authors: Guenther Lillian M. , Dharia Neekesh V. , Ross Linda , Conway Amy , Robichaud Amanda L. , Catlett Jerrel L. , Wechsler Caroline S. , Frank Elizabeth S. , Goodale Amy , Church Alanna J. , Tseng Yuen-Yi , Guha Rajarshi , McKnight Crystal G. , Janeway Katherine A. , Boehm Jesse S. , Mora Jaume , Davis Mindy I. , Alexe Gabriela , Piccioni Federica , Stegmaier Kimberly
Published: April 2023

Related to Figure 6
Supplemental Figure 3 from A Combination CDK4/6 and IGF1R Inhibitor Strategy for Ewing Sarcoma
Authors: Guenther Lillian M. , Dharia Neekesh V. , Ross Linda , Conway Amy , Robichaud Amanda L. , Catlett Jerrel L. , Wechsler Caroline S. , Frank Elizabeth S. , Goodale Amy , Church Alanna J. , Tseng Yuen-Yi , Guha Rajarshi , McKnight Crystal G. , Janeway Katherine A. , Boehm Jesse S. , Mora Jaume , Davis Mindy I. , Alexe Gabriela , Piccioni Federica , Stegmaier Kimberly
Published: April 2023

Related to Figure 3
Supplemental Figure 2 from A Combination CDK4/6 and IGF1R Inhibitor Strategy for Ewing Sarcoma
Authors: Guenther Lillian M. , Dharia Neekesh V. , Ross Linda , Conway Amy , Robichaud Amanda L. , Catlett Jerrel L. , Wechsler Caroline S. , Frank Elizabeth S. , Goodale Amy , Church Alanna J. , Tseng Yuen-Yi , Guha Rajarshi , McKnight Crystal G. , Janeway Katherine A. , Boehm Jesse S. , Mora Jaume , Davis Mindy I. , Alexe Gabriela , Piccioni Federica , Stegmaier Kimberly
Published: April 2023

Related to Figure 3
Supplementary Figures S1-S8 from Novel MYBL1 Gene Rearrangements with Recurrent MYBL1–NFIB Fusions in Salivary Adenoid Cystic Carcinomas Lacking t(6;9) Translocations
Authors: Mitani Yoshitsugu , Liu Bin , Rao Pulivarthi H. , Borra Vishnupriya J. , Zafereo Mark , Weber Randal S. , Kies Merrill , Lozano Guillermina , Futreal P. Andrew , Caulin Carlos , El-Naggar Adel K.
Published: April 2023

Supplementary Figure S1. Global chromosomal rearrangements in ACCs. Supplementary Figure S2. Shared mutated genes in ACC with MYB-/MYBL1-NFIB fusions and Non-fusion. Supplementary Figure. S3. Characterization of MYBL1-NFIB fusion transcripts. Supplementary Figure S4. (A-E) Nucleotide and Amino acid of MYBL1-NFIB fusion genes. Supplementary Figure S5. Characterization of MYBL1-YTHDF3 fusion transcripts. Supplementary Figure S6. Characterization of MYBL1 truncations. Supplementary Figure S7. Analysis of NFIB fusions at the 5'end of the gene. Supplementary Figure S8. Kaplan-Meier survival curves of ACCs patients.
Figure S5 from Lymphotoxin-β Interacts with Methylated EGFR to Mediate Acquired Resistance to Cetuximab in Head and Neck Cancer
Authors: Hsu Dennis Shin-Shian , Hwang Wei-Lun , Yuh Chiou-Hwa , Chu Chen-Hsi , Ho Yang-Hui , Chen Pon-Bo , Lin Han-Syuan , Lin Hua-Kuo , Wu Shih-Pei , Lin Chih-Yi , Hsu Wen-Hao , Lan Hsin-Yi , Wang Hsiao-Jung , Tai Shyh-Kuan , Hung Mien-Chie , Yang Muh-Hwa
Published: April 2023

Interaction between LTβ and methylated EGFR activates EGFR and induces cetuximab resistance
Supplementary Figure S1 from The PARP Inhibitor Veliparib Can Be Safely Added to Bendamustine and Rituximab and Has Preliminary Evidence of Activity in B-Cell Lymphoma
Authors: Soumerai Jacob D. , Zelenetz Andrew D. , Moskowitz Craig H. , Palomba M. Lia , Hamlin Paul A. , Noy Ariela , Straus David J. , Moskowitz Alison J. , Younes Anas , Matasar Matthew J. , Horwitz Steven M. , Portlock Carol S. , Konner Jason A. , Gounder Mrinal M. , Hyman David M. , Voss Martin H. , Fury Matthew G. , Gajria Devika , Carvajal Richard D. , Ho Alan L. , Beumer Jan H. , Kiesel Brian , Zhang Zhigang , Chen Alice , Little Richard F. , Jarjies Christine , Dang Thu O. , France Fallon , Mishra Nishant , Gerecitano John F.
Published: April 2023

CONSORT Diagram.
Figure S4 from Lymphotoxin-β Interacts with Methylated EGFR to Mediate Acquired Resistance to Cetuximab in Head and Neck Cancer
Authors: Hsu Dennis Shin-Shian , Hwang Wei-Lun , Yuh Chiou-Hwa , Chu Chen-Hsi , Ho Yang-Hui , Chen Pon-Bo , Lin Han-Syuan , Lin Hua-Kuo , Wu Shih-Pei , Lin Chih-Yi , Hsu Wen-Hao , Lan Hsin-Yi , Wang Hsiao-Jung , Tai Shyh-Kuan , Hung Mien-Chie , Yang Muh-Hwa
Published: April 2023

Activation of EGFR and the NF-κB pathway in cetuximab-resistant cells
Figure S2 from Lymphotoxin-β Interacts with Methylated EGFR to Mediate Acquired Resistance to Cetuximab in Head and Neck Cancer
Authors: Hsu Dennis Shin-Shian , Hwang Wei-Lun , Yuh Chiou-Hwa , Chu Chen-Hsi , Ho Yang-Hui , Chen Pon-Bo , Lin Han-Syuan , Lin Hua-Kuo , Wu Shih-Pei , Lin Chih-Yi , Hsu Wen-Hao , Lan Hsin-Yi , Wang Hsiao-Jung , Tai Shyh-Kuan , Hung Mien-Chie , Yang Muh-Hwa
Published: April 2023

Snail locates upstream to LTβ upregulates its expression, and LTβ induces EMT
Supplementary Tables from Preclinical Evaluation of Intravesical Cisplatin Nanoparticles for Non–Muscle-Invasive Bladder Cancer
Authors: Kates Max , Date Abhijit , Yoshida Takahiro , Afzal Umara , Kanvinde Pranjali , Babu Taarika , Sopko Nikolai A. , Matsui Hotaka , Hahn Noah M. , McConkey David J. , Baras Alexander , Hanes Justin , Ensign Laura , Bivalacqua Trinity J.
Published: April 2023

Supplementary Table 1: Nanoparticle physicochemical characteristics. Table S2: IC50 values of various formulations against various bladder cancer cell lines.
Figures S1-S4 from Preclinical Evaluation of Intravesical Cisplatin Nanoparticles for Non–Muscle-Invasive Bladder Cancer
Authors: Kates Max , Date Abhijit , Yoshida Takahiro , Afzal Umara , Kanvinde Pranjali , Babu Taarika , Sopko Nikolai A. , Matsui Hotaka , Hahn Noah M. , McConkey David J. , Baras Alexander , Hanes Justin , Ensign Laura , Bivalacqua Trinity J.
Published: April 2023

Supplementary Figure 1: Transmission electron micrographs of PAA-CDDP NPs, PEGlow-PAA-CDDP NPs and PEGhigh-PAA-CDDP NPs (Scale bars = 500 nm). Supplementary Figure 2. Apoptosis was compared in RT4 cells treated with CDDP and PAA-CDDP NPs. DNA (blue, stained with hoechst33342), apoptotic cells (green, stained with Apoxin), and dead cells (red, stained with propidium iodide). Both formulations induced apoptosis in RT4 cells. Supplementary Figure 3: Images of gross tissue size supported the increased bladder weights in the CDDP treated group after 3 weekly administrations compared to PAA-CDDP NP, PEGlow-PAA-CDDP NPs and untreated control. Supplementary Figure 4. (A) Representative IHC sections stained for cleaved caspase 3 (brown) of rats treated with intravesical CDDP solution or intravesical PAA-CDDP NPs. (B) No significant differences in caspase 3+ cells were identified between treatment groups.
Supplementary Data from Complete Remission with Reduction of High-Risk Clones following Haploidentical NK-Cell Therapy against MDS and AML
Authors: Björklund Andreas T. , Carlsten Mattias , Sohlberg Ebba , Liu Lisa L. , Clancy Trevor , Karimi Mohsen , Cooley Sarah , Miller Jeffrey S. , Klimkowska Monika , Schaffer Marie , Watz Emma , Wikström Kristina , Blomberg Pontus , Wahlin Björn Engelbrekt , Palma Marzia , Hansson Lotta , Ljungman Per , Hellström-Lindberg Eva , Ljunggren Hans-Gustaf , Malmberg Karl-Johan
Published: April 2023

Supplementary Figures and Tables Supplemental Figure 1. Persistence of donor NK cells in vivo. (A) Frequency of patients with detectable donor NK cells in peripheral blood (PB) at day (d)7 and/or 14 after NK cell infusion in nonresponders (NR) and responders (R). (B) Identification of CD56+ donor NK cells based on expression of donor-unique HLA class I molecules (HLA-A2 for P3 and HLA-11 for P11). Shown are donor NK cells in the cell product prior to infusion (upper part) and in the recipient (lower part) day 21 (P3) or day 14 (P11) after NK cell infusion. Supplemental Figure 2. NK cell product repertoires. (A) Representative staining for CD56dim NK cell marker expression. Summary of results for (B) geometrical mean fluorescence intensity (GeoMFI) of perforin, Granzyme B, CXCR4, NKG2D and DNAM expression for CD56dim NK cells. (C) Frequencies of CD56dim NK cells responding with degranulation (CD107a) and IFN-γ production following coculture with K562 target cells. (D) NK cell differentiation stages as defined by CD57, KIR and NKG2A expression. (E) Frequencies of CD56dim NK cells expressing zero, one or multiple KIRs. Non-responders (NR; filled circles, n=3-5) and responders (R; open squares, n=5). Supplemental Figure 3. Clonal evolution in relapse patients. Visualization of presence and allelic burden of clones present in bone marrow of (A) P5 and (B) P14, pre and post NK cell treatment and at relapse. Supplemental Figure 4. Recipient NK cell responses. (A) Separation of donor (Do) and recipient NK cells based on donor unique HLA class I molecules. Shown are representative examples for HLA-A2, HLA-11, HLA-B7 and HLA-B13 with donor NK cells in donor product (gated upper part) and recipient NK cells (gated lower part) at day 14/21 post NK cell infusion. (B) Representative staining of CD69 and Ki-67 on CD3- CD56dim NK cells shown for donor (HLA+) cells and patient (HLA) cells from a non-responder (NR) and a responder (R). (C-D) Summary of results for frequencies of Ki-67+ and CD69+ CD56dim NK cells for all evaluable patients. (Do, filled triangles, n=9), (NR, filled circles, n=4) and (R, open squares, n=3). Supplemental Figure 5. Activation of Treg post NK cell infusion. (A) Representative staining for expression of Ki-67, PD-1 and CTLA-4 for CD3+CD4+CD127- FoxP3+ Treg pre and d28 post NK cell infusion. (B-E) Treg marker expression for non-responder (NR; filled circles, n=6-7) and responders (R; open squares, n=5). Supplemental Tables 1-3
Supplementary Data S1A-S9 from Trabectedin Inhibits EWS-FLI1 and Evicts SWI/SNF from Chromatin in a Schedule-dependent Manner
Authors: Harlow Matt L. , Chasse Maggie H. , Boguslawski Elissa A. , Sorensen Katie M. , Gedminas Jenna M. , Kitchen-Goosen Susan M. , Rothbart Scott B. , Taslim Cenny , Lessnick Stephen L. , Peck Anderson S. , Madaj Zachary B. , Bowman Megan J. , Grohar Patrick J.
Published: April 2023

Supplementary Data S1A-S9
Table S2 from PDK1 Mediates NOTCH1-Mutated Head and Neck Squamous Carcinoma Vulnerability to Therapeutic PI3K/mTOR Inhibition
Authors: Sambandam Vaishnavi , Frederick Mitchell J. , Shen Li , Tong Pan , Rao Xiayu , Peng Shaohua , Singh Ratnakar , Mazumdar Tuhina , Huang Chenfei , Li Qiuli , Pickering Curtis R. , Myers Jeffery N. , Wang Jing , Johnson Faye M.
Published: April 2023

Table S2. Fifty percent inhibitory concentration (IC50) and seventy percent inhibitory concentration (IC70) values for the seven PI3K/mTOR pathway inhibitors tested
Table S1 from PDK1 Mediates NOTCH1-Mutated Head and Neck Squamous Carcinoma Vulnerability to Therapeutic PI3K/mTOR Inhibition
Authors: Sambandam Vaishnavi , Frederick Mitchell J. , Shen Li , Tong Pan , Rao Xiayu , Peng Shaohua , Singh Ratnakar , Mazumdar Tuhina , Huang Chenfei , Li Qiuli , Pickering Curtis R. , Myers Jeffery N. , Wang Jing , Johnson Faye M.
Published: April 2023

Table S1. Antibodies used in Western blot analyses
Figure S8 from PDK1 Mediates NOTCH1-Mutated Head and Neck Squamous Carcinoma Vulnerability to Therapeutic PI3K/mTOR Inhibition
Authors: Sambandam Vaishnavi , Frederick Mitchell J. , Shen Li , Tong Pan , Rao Xiayu , Peng Shaohua , Singh Ratnakar , Mazumdar Tuhina , Huang Chenfei , Li Qiuli , Pickering Curtis R. , Myers Jeffery N. , Wang Jing , Johnson Faye M.
Published: April 2023

Figure S8. Effect of the inhibition of multiple components of the PI3K/mTOR pathway in head and neck squamous cell carcinoma (HNSCC) cell lines. A. NOTCH1MUT cells (red text) and NOTCH1WT cells (black text) were treated with increasing concentrations (0-200 nM, 2-fold dilution) of GSK2126458 (a dual PI3K/mTOR inhibitor), BAY806946 (a pan-PI3K inhibitor), rapamycin and ridaforolimus (two mTOR inhibitors), and MK2206 (an AKT inhibitor) for 72 hours, and cell viability was assessed using the CellTiter-Glo assay. B. The protein p-S6 (S240/244) bands in Figure 2D were quantified using ImageJ software and normalized to β-actin expression, and the fold change from the control was calculated. Data are the means {plus minus} standard errors for three cell lines. *p<0.05, unpaired one-tailed Student t-test.
Supplementary Figure S1 - S7 from Dual Src and MEK Inhibition Decreases Ovarian Cancer Growth and Targets Tumor Initiating Stem-Like Cells
Authors: Simpkins Fiona , Jang Kibeom , Yoon Hyunho , Hew Karina E. , Kim Minsoon , Azzam Diana J. , Sun Jun , Zhao Dekuang , Ince Tan A. , Liu Wenbin , Guo Wei , Wei Zhi , Zhang Gao , Mills Gordon B. , Slingerland Joyce M.
Published: April 2023

Supplemental Fig S1. Effects of MEK and Src siRNA and drug inhibitors on cell cycle and signaling; Supplemental Fig S2. Quantitative densitometric analysis of Western blots shown in Figure 2 G & H for p27, pSrc, and pMAPK; Supplemental Fig S3. Effects of long-term saracatinib exposure to increase MEK and upstream kinase activation; Supplemental Fig S4. Densitometry of Western blots in Figure 3; Supplemental Fig S5. Additional data from GSEA; Supplemental Fig S6. Supplemental data for stem cell quantitation in PEO1R, OCI-C5x, OCI-P5x and OCI-U1a; Supplemental Fig S7. Photomicrographs of Ki67, Caspase 3 and ALDH1 in xenograft tumors in Figure 6A.
Supplementary Figure Legends from Dual Src and MEK Inhibition Decreases Ovarian Cancer Growth and Targets Tumor Initiating Stem-Like Cells
Authors: Simpkins Fiona , Jang Kibeom , Yoon Hyunho , Hew Karina E. , Kim Minsoon , Azzam Diana J. , Sun Jun , Zhao Dekuang , Ince Tan A. , Liu Wenbin , Guo Wei , Wei Zhi , Zhang Gao , Mills Gordon B. , Slingerland Joyce M.
Published: April 2023

Supplementary Figure Legends
Figure S5 from PDK1 Mediates NOTCH1-Mutated Head and Neck Squamous Carcinoma Vulnerability to Therapeutic PI3K/mTOR Inhibition
Authors: Sambandam Vaishnavi , Frederick Mitchell J. , Shen Li , Tong Pan , Rao Xiayu , Peng Shaohua , Singh Ratnakar , Mazumdar Tuhina , Huang Chenfei , Li Qiuli , Pickering Curtis R. , Myers Jeffery N. , Wang Jing , Johnson Faye M.
Published: April 2023

Figure S5. Effects of PI3K/mTOR signaling inhibition on the survival of NOTCH1MUT and NOTCH1WT head and neck squamous cell carcinoma (HNSCC) cell lines in vitro. A. The Annexin V/propidium iodide assay was used to assess apoptosis in HNSCC cells that had the indicated NOTCH1 and PIK3CA mutations and were treated with 500 nM BAY806946 or 1 µM PQR309. Values are the means {plus minus} standard deviations of three independent experiments. *p<0.05, unpaired two-tailed Student t-test. B. NOTCH1MUT lines (red text) and NOTCH1WT lines (black text) were treated with increasing concentrations of PQR309 and BAY806946 for 3 hours, and then Western blotting was used to assess levels of p-AKT (S473). C. NOTCH1WT lines (black text), NOTCH1MUT lines (red text), and PIK3CAMUT lines (blue text) were treated with 50 nM GSK2126458 (GSK212) and then pulse-labeled with BrDU and counterstained with 7-AAD for flow cytometry.
Figure S3 from PDK1 Mediates NOTCH1-Mutated Head and Neck Squamous Carcinoma Vulnerability to Therapeutic PI3K/mTOR Inhibition
Authors: Sambandam Vaishnavi , Frederick Mitchell J. , Shen Li , Tong Pan , Rao Xiayu , Peng Shaohua , Singh Ratnakar , Mazumdar Tuhina , Huang Chenfei , Li Qiuli , Pickering Curtis R. , Myers Jeffery N. , Wang Jing , Johnson Faye M.
Published: April 2023

Figure S3: Sensitivity to PI3K/mTOR pathway inhibitors is not significantly associated with PI3K/mTOR pathway alterations A. The heat map depicts the association between 19 genetic mutations in the PI3K/mTOR pathway (left column) and GSK2126458 sensitivity in 59 head and neck squamous cell carcinoma (HNSCC) cell lines. P values were calculated using the Fisher exact test; no significant associations were observed. Similar results were obtained with other PI3K inhibitors using the Wilcoxon rank-sum test (data not shown). Black boxes in the heatmap indicate mutations; white (i.e., absent) boxes indicate wild type genes; blue boxes indicate non-canonical mutations in the PIK3CA gene. The black vertical line in the bar graph indicates the peak plasma concentration of GSK2126458. B. Spearman correlation analysis was used to assess associations between IC70 values and PI3K proteomic scores, including for p-AKT (T308), p-AKT (S473), p-GSK3 (S9), p-GSK3-α/β (S9/21), p-p27 (T157), p-p27 (T198), p-PRAS40 (T246), INPP4B, and PTEN; no significant correlations were detected. C. Spearman correlation analysis was used to assess associations between IC70 values and mTOR proteomic scores, including for Tp-4EBP1 (S65), p-4EBP1 (T37/46), p4EBP1 (T70), p-mTOR (S2488), p-p70S6K (T389), p-S6 (S235/236), and p-S6 (S240/244); no significant correlations were detected. The dashed blue lines indicate trend line and the shaded area represent 95% confidence interval.
Figure S2 from PDK1 Mediates NOTCH1-Mutated Head and Neck Squamous Carcinoma Vulnerability to Therapeutic PI3K/mTOR Inhibition
Authors: Sambandam Vaishnavi , Frederick Mitchell J. , Shen Li , Tong Pan , Rao Xiayu , Peng Shaohua , Singh Ratnakar , Mazumdar Tuhina , Huang Chenfei , Li Qiuli , Pickering Curtis R. , Myers Jeffery N. , Wang Jing , Johnson Faye M.
Published: April 2023

Figure S2. Relationship of NOTCH1 protein expression, activation, and mutation in head and neck squamous cell carcinoma (HNSCC) tumors and cell lines. A. The basal protein expression levels of NOTCH1 were compared between NOTCH1WT (n=170) and NOTCH1MUT (n=38) tumors available in The Cancer Genome Atlas (TCGA) using a two-sample t-test. B-E. Basal NOTCH1 (B and E) and NOTCH intracellular domain (NICD) (C and D) protein expression was compared with drug sensitivity as measured by area under curve (AUC) for all 59 HNSCC cell lines (B and C), NOTCH1WT cells only (n=45) (D), and with NOTCH1MUT cells only (n=14) (E). P values were calculated with Spearman rho correlation analysis. The dashed blue lines indicate trend line and the shaded area represent 95% confidence interval.
Supplementary Data from A Novel mTORC1/2 Inhibitor (MTI-31) Inhibits Tumor Growth, Epithelial–Mesenchymal Transition, Metastases, and Improves Antitumor Immunity in Preclinical Models of Lung Cancer
Authors: Zhang Qianwen , Zhang Yan , Chen Yaqing , Qian Jianchang , Zhang Xuesai , Yu Ker
Published: April 2023

Supplement data
Figure legends S1-S4 from Prevalence and Cellular Distribution of Novel Immune Checkpoint Targets Across Longitudinal Specimens in Treatment-naïve Melanoma Patients: Implications for Clinical Trials
Authors: Edwards Jarem , Tasker Annie , Pires da Silva Inês , Quek Camelia , Batten Marcel , Ferguson Angela , Allen Ruth , Allanson Benjamin , Saw Robyn P.M. , Thompson John F. , Menzies Alexander M. , Palendira Umaimainthan , Wilmott James S. , Long Georgina V. , Scolyer Richard A.
Published: April 2023

These are the supplementary data figure legends (S1-S4)
Supplementary Data from ATR Inhibition Potentiates the Radiation-induced Inflammatory Tumor Microenvironment
Authors: Dillon Magnus T. , Bergerhoff Katharina F. , Pedersen Malin , Whittock Harriet , Crespo-Rodriguez Eva , Patin Emmanuel C. , Pearson Alex , Smith Henry G. , Paget James T.E. , Patel Radhika R. , Foo Shane , Bozhanova Galabina , Ragulan Chanthirika , Fontana Elisa , Desai Krisha , Wilkins Anna C. , Sadanandam Anguraj , Melcher Alan , McLaughlin Martin , Harrington Kevin J.
Published: April 2023

Supplementary figures and tables
S1-4 from Focal Irradiation and Systemic TGFβ Blockade in Metastatic Breast Cancer
Authors: Formenti Silvia C. , Lee Percy , Adams Sylvia , Goldberg Judith D. , Li Xiaochun , Xie Mike W. , Ratikan Josephine A. , Felix Carol , Hwang Lin , Faull Kym F. , Sayre James W. , Hurvitz Sara , Glaspy John A. , Comin-Anduix Begoña , Demaria Sandra , Schaue Dörthe , McBride William H.
Published: April 2023

Supplementary Table S1. Antibodies and dextramers used for flow cytometric analysis Supplementary Table S2. Patients with one or more treatment positively-related (maximum grade possible, probable, definite) AEs by treatment arm Supplementary Table S3. Levels of circulating tumor-specific CD8+ T cells with reactivity for JARID1B, Muc1 or Her2 in breast cancer patients with HLA-A*0201 status Supplementary Table S4. Humoral immune responses were not significantly affected following TGFβ blockade and radiation Supplementary Figure S1: Study schema Supplementary Figure S2. Gating strategy in panel 1. Supplementary Figure S3. Gating strategy in panel 2. Supplementary Figure S4. Changes in PBMC, survivin- and JARID1B-reactive CD8 T cells in response to TGFβ blockade and radiation. Supplementary Figure S5. Diametrically opposing dynamics in the myeloid suppressor compartment versus the suppressor T cell pool in response to TGFβ blockade and radiation. Supplementary Figure S6. Changes in plasma levels of tryptophan and kynurenine in response to TGFβ blockade and radiation.
Table S1 and S2 from Human Papillomavirus DNA Methylation as a Biomarker for Cervical Precancer: Consistency across 12 Genotypes and Potential Impact on Management of HPV-Positive Women
Authors: Clarke Megan A. , Gradissimo Ana , Schiffman Mark , Lam Jessica , Sollecito Christopher C. , Fetterman Barbara , Lorey Thomas , Poitras Nancy , Raine-Bennett Tina R. , Castle Philip E. , Wentzensen Nicolas , Burk Robert D.
Published: April 2023

Table S1 shows type-specific associations of methylation with CIN3/AIS. Table S2 shows the correlation of methylation across CpG sites, by HPV type
Supplementary Tables 1-8 from Phase I Study of CC-486 Alone and in Combination with Carboplatin or nab-Paclitaxel in Patients with Relapsed or Refractory Solid Tumors
Authors: Von Hoff Daniel D. , Rasco Drew W. , Heath Elisabeth I. , Munster Pamela N. , Schellens Jan H.M. , Isambert Nicolas , Tourneau Christophe Le , O'Neil Bert , Mathijssen Ron H.J. , Lopez-Martin Jose A. , Edenfield W. Jeff , Martin Miguel , LoRusso Patricia M. , Bray Gordon L. , DiMartino Jorge , Nguyen Aaron , Liu Kejian , Laille Eric , Bendell Johanna C.
Published: April 2023

Table S1. CC-486 Plus Carboplatin Dose Levels in Part 1 Arm A Table S2. CC-486 Plus nab-Paclitaxel Dose Levels in Part 1 Arm B Table S3. CC-486 Dose Levels in Part 1 Arm C Table S4. Number of Patients With Treatment Emergent Adverse Events for Part 1 Table S5. Number of Patients With Treatment-Emergent Adverse Events in Any Treatment Arm in Part 2 Table S6. Mean CC-486 Plasma Pharmacokinetic Parameters Table S7. Efficacy of CC-486 Alone or in Combination With Carboplatin or nab-Paclitaxel in Part 2 Table S8. Prior Treatment History of NPV Patients
Supplementary Methods Data from Phase I Study of CC-486 Alone and in Combination with Carboplatin or nab-Paclitaxel in Patients with Relapsed or Refractory Solid Tumors
Authors: Von Hoff Daniel D. , Rasco Drew W. , Heath Elisabeth I. , Munster Pamela N. , Schellens Jan H.M. , Isambert Nicolas , Tourneau Christophe Le , O'Neil Bert , Mathijssen Ron H.J. , Lopez-Martin Jose A. , Edenfield W. Jeff , Martin Miguel , LoRusso Patricia M. , Bray Gordon L. , DiMartino Jorge , Nguyen Aaron , Liu Kejian , Laille Eric , Bendell Johanna C.
Published: April 2023

Pharmacodynamic Assessments
Supplementary Figure 3 from Phase I Study of CC-486 Alone and in Combination with Carboplatin or nab-Paclitaxel in Patients with Relapsed or Refractory Solid Tumors
Authors: Von Hoff Daniel D. , Rasco Drew W. , Heath Elisabeth I. , Munster Pamela N. , Schellens Jan H.M. , Isambert Nicolas , Tourneau Christophe Le , O'Neil Bert , Mathijssen Ron H.J. , Lopez-Martin Jose A. , Edenfield W. Jeff , Martin Miguel , LoRusso Patricia M. , Bray Gordon L. , DiMartino Jorge , Nguyen Aaron , Liu Kejian , Laille Eric , Bendell Johanna C.
Published: April 2023

Correlation analysis between pharmacodynamic and pharmacokinetic findings in part 1
Supplementary Figures from Lipidomic Profiling Links the Fanconi Anemia Pathway to Glycosphingolipid Metabolism in Head and Neck Cancer Cells
Authors: Zhao Xueheng , Brusadelli Marion G. , Sauter Sharon , Butsch Kovacic Melinda , Zhang Wujuan , Romick-Rosendale Lindsey E. , Lambert Paul F. , Setchell Kenneth D.R. , Wells Susanne I.
Published: April 2023

Supplementary Figures 1-6 Supplementary Figure 1a Identification of ganglioside GM3 (d34:0) by UPLC-MSe. Putative biomarker GM3(d34:0) by database search was confirmed by authentic standard with retention time, fragmentation ions in EIC. Mass chromatogram was EIC using the molecular ion [MW-H]-. Mass spectrum is for illustration with showing only extracted ions of interest and relative intensity. Supplementary Figure 1b Identification of ganglioside GM3 (d34:2) by UPLC-MSe. Putative biomarker GM3(d34:2) by database search was confirmed by authentic standard with retention time, fragmentation ions in EIC. Mass chromatogram was EIC using the molecular ion [MW-H]-. Mass spectrum is for illustration with showing only extracted ions of interest and relative intensity. Supplementary Figure 2 Profile of gangliosides, lactosylceramides, glucosylceramides in the NIKS cells: Gangliosides GM3, GM1, and GD3, and lactosylceramides were significantly up-regulated in FANCD2 knockdown NIKS cells. *P < 0.05; **P < 0.01; ***P < 0.001; ****P < 0.0001 (two-tailed t test); Volcano plot indicated ganglioside GM3 species are significantly altered in the FANCD2 knockdown NIKS cells. p-value was calculated with 2-tailed student's t test, thresholds for significance: Bonferroni adjusted p-value < 0.05, fold change > 1.5. Supplementary Figure 3a Gangliosides GM3, GM1, and GD3, and lactosylceramides were significantly up-regulated in FANCD2 knockdown NIKS cells. *P < 0.05; ****P < 0.0001 (two-tailed t test) Supplementary Figure 3b Gangliosides GM3, GM1, and GD3, and lactosylceramides were significantly up-regulated in FANCD2 knockdown NOKS cells. **P < 0.01, ***P < 0.001 (two-tailed t test). Supplementary Figure 3c Gangliosides GM3, GM1, and GD3, and lactosylceramides were significantly up-regulated in FANCD2 knockdown UMSCC47 cells. **P < 0.01, ****P < 0.0001 (two-tailed t test). Supplementary Figure 4 Profile of ganglioside GM1 and GD3 in the UM-SCC1, UMSCC-47, NOKS and VU1365 cells: Gangliosides GM1, and GD3 with different acyl chain length, were measured in FANCD2 knockdown UM-SCC1, UM-SCC47, NOKS, and Vu1365 cells. *P < 0.05; **P < 0.01; ***P < 0.001; ****P < 0.0001 (two-tailed t test) Supplementary Figure 5 Ganglioside GM3 (d34:1), GM3 (d34:0) and GM3 (d34:2) decrease in NTsh, FANCD2sh and FANCJsh UMSCC-1 cells after NB-DNJ exposure Supplementary Figure 6 NTsh and FANCD2sh NIKS cells (a) and UMSCC-47 cells (b) were plated at equal cell numbers, and NB-DNJ was added following cell attachment, and replenished in fresh media after 24 hrs
Supplementary Figure S1 from FDA Approval Summary: Ivosidenib for Relapsed or Refractory Acute Myeloid Leukemia with an Isocitrate Dehydrogenase-1 Mutation
Authors: Norsworthy Kelly J. , Luo Lola , Hsu Vicky , Gudi Ramadevi , Dorff Sarah E. , Przepiorka Donna , Deisseroth Albert , Shen Yuan-Li , Sheth Christopher M. , Charlab Rosane , Williams Gene M. , Goldberg Kirsten B. , Farrell Ann T. , Pazdur Richard
Published: April 2023

Rate of CR+CRh by subgroup
supplementary Table 1 from Assessing Therapeutic Efficacy of MEK Inhibition in a KRASG12C-Driven Mouse Model of Lung Cancer
Authors: Li Shuai , Liu Shengwu , Deng Jiehui , Akbay Esra A. , Hai Josephine , Ambrogio Chiara , Zhang Long , Zhou Fangyu , Jenkins Russell W. , Adeegbe Dennis O. , Gao Peng , Wang Xiaoen , Paweletz Cloud P. , Herter-Sprie Grit S. , Chen Ting , Gutiérrez-Quiceno Laura , Zhang Yanxi , Merlino Ashley A. , Quinn Max M. , Zeng Yu , Yu Xiaoting , Liu Yuting , Fan Lichao , Aguirre Andrew J. , Barbie David A. , Yi Xianghua , Wong Kwok-Kin
Published: April 2023

Supplementary Table 1
Figure S5 from Single-Cell Analyses of Prostate Cancer Liquid Biopsies Acquired by Apheresis
Authors: Lambros Maryou B. , Seed George , Sumanasuriya Semini , Gil Veronica , Crespo Mateus , Fontes Mariane , Chandler Rob , Mehra Niven , Fowler Gemma , Ebbs Berni , Flohr Penny , Miranda Susana , Yuan Wei , Mackay Alan , Ferreira Ana , Pereira Rita , Bertan Claudia , Figueiredo Ines , Riisnaes Ruth , Rodrigues Daniel Nava , Sharp Adam , Goodall Jane , Boysen Gunther , Carreira Suzanne , Bianchini Diletta , Rescigno Pasquale , Zafeiriou Zafeiris , Hunt Joanne , Moloney Deirdre , Hamilton Lucy , Neves Rui P. , Swennenhuis Joost , Andree Kiki , Stoecklein Nikolas H. , Terstappen Leon W.M.M. , de Bono Johann S.
Published: April 2023

Organoid cultures of CTCs acquired by apheresis from patient P05: a) Dendrogram and heat map of hierarchical clustering, based on Euclidean distance, for patient P05 evaluating CTC (green bars) and organoid CNAs (red). b) Micrographs of two organoids from P05 with scale bar in bottom left (100Âµm). c) Phylogenetic tree showing the cultured organoids have CNA that cluster with CTCs. d) Two organoids and 3 CTCs with truncal CNA including shared BRCA2 loss and AR amplification but sub-clonal chromosome 1 aberrations.
Figure S4 from Single-Cell Analyses of Prostate Cancer Liquid Biopsies Acquired by Apheresis
Authors: Lambros Maryou B. , Seed George , Sumanasuriya Semini , Gil Veronica , Crespo Mateus , Fontes Mariane , Chandler Rob , Mehra Niven , Fowler Gemma , Ebbs Berni , Flohr Penny , Miranda Susana , Yuan Wei , Mackay Alan , Ferreira Ana , Pereira Rita , Bertan Claudia , Figueiredo Ines , Riisnaes Ruth , Rodrigues Daniel Nava , Sharp Adam , Goodall Jane , Boysen Gunther , Carreira Suzanne , Bianchini Diletta , Rescigno Pasquale , Zafeiriou Zafeiris , Hunt Joanne , Moloney Deirdre , Hamilton Lucy , Neves Rui P. , Swennenhuis Joost , Andree Kiki , Stoecklein Nikolas H. , Terstappen Leon W.M.M. , de Bono Johann S.
Published: April 2023

Heatmaps presenting unsupervised hierarchical clustering based on CNA and Euclidean distance, of all the samples for each patient. Each individual patient is depicted by number from left to right, with chromosomal aberrations from top to bottom. Tumor biopsies are identified by black bars, and CTCs by green bars, at the bottom of the heatmap.
Figure S3 from Single-Cell Analyses of Prostate Cancer Liquid Biopsies Acquired by Apheresis
Authors: Lambros Maryou B. , Seed George , Sumanasuriya Semini , Gil Veronica , Crespo Mateus , Fontes Mariane , Chandler Rob , Mehra Niven , Fowler Gemma , Ebbs Berni , Flohr Penny , Miranda Susana , Yuan Wei , Mackay Alan , Ferreira Ana , Pereira Rita , Bertan Claudia , Figueiredo Ines , Riisnaes Ruth , Rodrigues Daniel Nava , Sharp Adam , Goodall Jane , Boysen Gunther , Carreira Suzanne , Bianchini Diletta , Rescigno Pasquale , Zafeiriou Zafeiris , Hunt Joanne , Moloney Deirdre , Hamilton Lucy , Neves Rui P. , Swennenhuis Joost , Andree Kiki , Stoecklein Nikolas H. , Terstappen Leon W.M.M. , de Bono Johann S.
Published: April 2023

Unsupervised clustering analyses of all samples: Fan presentation of unsupervised clustering of all CTCs, tissue biopsies and organoids evaluated in this study. Each CTC is annotated as a circle, each tissue sample as a square, and an organoid as a triangle. Each apheresis patient is depicted by a color. CTCs largely cluster with tumor biopsies from the same patient although as a result of intrapatient heterogeneity some clustered away.
Figure S1 from Single-Cell Analyses of Prostate Cancer Liquid Biopsies Acquired by Apheresis
Authors: Lambros Maryou B. , Seed George , Sumanasuriya Semini , Gil Veronica , Crespo Mateus , Fontes Mariane , Chandler Rob , Mehra Niven , Fowler Gemma , Ebbs Berni , Flohr Penny , Miranda Susana , Yuan Wei , Mackay Alan , Ferreira Ana , Pereira Rita , Bertan Claudia , Figueiredo Ines , Riisnaes Ruth , Rodrigues Daniel Nava , Sharp Adam , Goodall Jane , Boysen Gunther , Carreira Suzanne , Bianchini Diletta , Rescigno Pasquale , Zafeiriou Zafeiris , Hunt Joanne , Moloney Deirdre , Hamilton Lucy , Neves Rui P. , Swennenhuis Joost , Andree Kiki , Stoecklein Nikolas H. , Terstappen Leon W.M.M. , de Bono Johann S.
Published: April 2023

Clinical data: a) Summary of prior treatments of all 14 patients prior to apheresis. b) A histogram presenting the lymphocyte and neutrophil counts (x109/L) in peripheral blood pre- and post-apheresis procedures.
Figure S2 from MELK Inhibition in Diffuse Intrinsic Pontine Glioma
Authors: Meel Michaël H. , de Gooijer Mark C. , Guillén Navarro Miriam , Waranecki Piotr , Breur Marjolein , Buil Levi C.M. , Wedekind Laurine E. , Twisk Jos W.R. , Koster Jan , Hashizume Rintaro , Raabe Eric H. , Montero Carcaboso Angel , Bugiani Marianna , van Tellingen Olaf , van Vuurden Dannis G. , Kaspers Gertjan J.L. , Hulleman Esther
Published: April 2023

Dose-response curves of JHH-DIPG-01 cultures to OTSSP167 after shRNA-mediated MELK knockdown.
Supplementary Tble S3 from Multi-omics Integration Analysis Robustly Predicts High-Grade Patient Survival and Identifies CPT1B Effect on Fatty Acid Metabolism in Bladder Cancer
Authors: Vantaku Venkatrao , Dong Jianrong , Ambati Chandrashekar R. , Perera Dimuthu , Donepudi Sri Ramya , Amara Chandra Sekhar , Putluri Vasanta , Ravi Shiva Shankar , Robertson Matthew J. , Piyarathna Danthasinghe Waduge Badrajee , Villanueva Mariana , von Rundstedt Friedrich-Carl , Karanam Balasubramanyam , Ballester Leomar Y. , Terris Martha K. , Bollag Roni J. , Lerner Seth P. , Apolo Andrea B. , Villanueva Hugo , Lee MinJae , Sikora Andrew G. , Lotan Yair , Sreekumar Arun , Coarfa Cristian , Putluri Nagireddy
Published: April 2023

Supplementary Table S3. Patient characteristics of bladder specimens used for the metabolomics and lipidomics profiling.
14-day toxicity study from The Anticancer Activity of a First-in-class Small-molecule Targeting PCNA
Authors: Gu Long , Lingeman Robert , Yakushijin Fumiko , Sun Emily , Cui Qi , Chao Jianfei , Hu Weidong , Li Hongzhi , Hickey Robert J. , Stark Jeremy M. , Yuan Yate-Ching , Chen Yuan , Vonderfecht Steven L. , Synold Timothy W. , Shi Yanhong , Reckamp Karen L. , Horne David , Malkas Linda H.
Published: April 2023

Supplementary report
Supplementary Table S4 from Multi-omics Integration Analysis Robustly Predicts High-Grade Patient Survival and Identifies CPT1B Effect on Fatty Acid Metabolism in Bladder Cancer
Authors: Vantaku Venkatrao , Dong Jianrong , Ambati Chandrashekar R. , Perera Dimuthu , Donepudi Sri Ramya , Amara Chandra Sekhar , Putluri Vasanta , Ravi Shiva Shankar , Robertson Matthew J. , Piyarathna Danthasinghe Waduge Badrajee , Villanueva Mariana , von Rundstedt Friedrich-Carl , Karanam Balasubramanyam , Ballester Leomar Y. , Terris Martha K. , Bollag Roni J. , Lerner Seth P. , Apolo Andrea B. , Villanueva Hugo , Lee MinJae , Sikora Andrew G. , Lotan Yair , Sreekumar Arun , Coarfa Cristian , Putluri Nagireddy
Published: April 2023

Supplementary Table S4. List of 519 differential metabolites, m/z, log fold change, and linear fold change.
Supplemental tables from Disruption of a −35 kb Enhancer Impairs CTCF Binding and MLH1 Expression in Colorectal Cells
Authors: Liu Qing , Thoms Julie A.I. , Nunez Andrea C. , Huang Yizhou , Knezevic Kathy , Packham Deborah , Poulos Rebecca C. , Williams Rachel , Beck Dominik , Hawkins Nicholas J. , Ward Robyn L. , Wong Jason W.H. , Hesson Luke B. , Sloane Mathew A. , Pimanda John E.
Published: April 2023

Supplementary data tables
Supplemental Methods and Materials from Disruption of a −35 kb Enhancer Impairs CTCF Binding and MLH1 Expression in Colorectal Cells
Authors: Liu Qing , Thoms Julie A.I. , Nunez Andrea C. , Huang Yizhou , Knezevic Kathy , Packham Deborah , Poulos Rebecca C. , Williams Rachel , Beck Dominik , Hawkins Nicholas J. , Ward Robyn L. , Wong Jason W.H. , Hesson Luke B. , Sloane Mathew A. , Pimanda John E.
Published: April 2023

Supplemental methods and supplemental figures 1-6
Supplementary Table S1 - S4 from Clinicopathological Risk Factors for an Invasive Breast Cancer Recurrence after Ductal Carcinoma In Situ—A Nested Case–Control Study
Authors: Visser Lindy L. , Elshof Lotte E. , Schaapveld Michael , van de Vijver Koen , Groen Emma J. , Almekinders Mathilde M. , Bierman Carolien , van Leeuwen Flora E. , Rutgers Emiel J. , Schmidt Marjanka K. , Lips Esther H. , Wesseling Jelle
Published: April 2023

Supplementary Tables
Supplementary Movie 1 from On-target Resistance to the Mutant-Selective EGFR Inhibitor Osimertinib Can Develop in an Allele-Specific Manner Dependent on the Original EGFR-Activating Mutation
Authors: Brown Benjamin P. , Zhang Yun-Kai , Westover David , Yan Yingjun , Qiao Huan , Huang Vincent , Du Zhenfang , Smith Jarrod A. , Ross Jeffrey S. , Miller Vincent A. , Ali Siraj , Bazhenova Lyudmila , Schrock Alexa B. , Meiler Jens , Lovly Christine M.
Published: April 2023

Supplementary Movie 1
Supplementary Methods from On-target Resistance to the Mutant-Selective EGFR Inhibitor Osimertinib Can Develop in an Allele-Specific Manner Dependent on the Original EGFR-Activating Mutation
Authors: Brown Benjamin P. , Zhang Yun-Kai , Westover David , Yan Yingjun , Qiao Huan , Huang Vincent , Du Zhenfang , Smith Jarrod A. , Ross Jeffrey S. , Miller Vincent A. , Ali Siraj , Bazhenova Lyudmila , Schrock Alexa B. , Meiler Jens , Lovly Christine M.
Published: April 2023

Supplementary Methods
Table S2 from Immunomarker Support Vector Machine Classifier for Prediction of Gastric Cancer Survival and Adjuvant Chemotherapeutic Benefit
Authors: Jiang Yuming , Xie Jingjing , Han Zhen , Liu Wei , Xi Sujuan , Huang Lei , Huang Weicai , Lin Tian , Zhao Liying , Hu Yanfeng , Yu Jiang , Zhang Qi , Li Tuanjie , Cai Shirong , Li Guoxin
Published: April 2023

Table S2. Antibody sources and staining conditions.
Supplemantary figure legends from Immunomarker Support Vector Machine Classifier for Prediction of Gastric Cancer Survival and Adjuvant Chemotherapeutic Benefit
Authors: Jiang Yuming , Xie Jingjing , Han Zhen , Liu Wei , Xi Sujuan , Huang Lei , Huang Weicai , Lin Tian , Zhao Liying , Hu Yanfeng , Yu Jiang , Zhang Qi , Li Tuanjie , Cai Shirong , Li Guoxin
Published: April 2023

Supplemantary figure legends
Supplementary Table S1 from SLC46A3 as a Potential Predictive Biomarker for Antibody–Drug Conjugates Bearing Noncleavable Linked Maytansinoid and Pyrrolobenzodiazepine Warheads
Authors: Kinneer Krista , Meekin John , Tiberghien Arnaud C. , Tai Yu-Tzu , Phipps Sandrina , Kiefer Christine Mione , Rebelatto Marlon C. , Dimasi Nazzareno , Moriarty Alyssa , Papadopoulos Kyriakos P. , Sridhar Sriram , Gregson Stephen J. , Wick Michael J. , Masterson Luke , Anderson Kenneth C. , Herbst Ronald , Howard Philip W. , Tice David A.
Published: April 2023

Supplementary table showing the relative expression of 43 target genes in a panel of EphA2-positive cell lines.
Table S1 from Targeting the CDK4/6-Rb Pathway Enhances Response to PI3K Inhibition in PIK3CA-Mutant Lung Squamous Cell Carcinoma
Authors: Shi Ruoshi , Li Ming , Raghavan Vibha , Tam Shirley , Cabanero Michael , Pham Nhu-An , Shepherd Frances A. , Moghal Nadeem , Tsao Ming-Sound
Published: April 2023

Supplementary Table S1
Table S3 from Pembrolizumab Plus Pegylated Interferon alfa-2b or Ipilimumab for Advanced Melanoma or Renal Cell Carcinoma: Dose-Finding Results from the Phase Ib KEYNOTE-029 Study
Authors: Atkins Michael B. , Hodi F. Stephen , Thompson John A. , McDermott David F. , Hwu Wen-Jen , Lawrence Donald P. , Dawson Nancy A. , Wong Deborah J. , Bhatia Shailender , James Marihella , Jain Lokesh , Robey Seth , Shu Xinxin , Homet Moreno Blanca , Perini Rodolfo F. , Choueiri Toni K. , Ribas Antoni
Published: April 2023

Treatment-Related Adverse Events Occurring in {greater than or equal to}1 Patient Treated With Pembrolizumab plus Ipilimumab
Table S3 from Validation of a Plasma-Based Comprehensive Cancer Genotyping Assay Utilizing Orthogonal Tissue- and Plasma-Based Methodologies
Authors: Odegaard Justin I. , Vincent John J. , Mortimer Stefanie , Vowles James V. , Ulrich Bryan C. , Banks Kimberly C. , Fairclough Stephen R. , Zill Oliver A. , Sikora Marcin , Mokhtari Reza , Abdueva Diana , Nagy Rebecca J. , Lee Christine E. , Kiedrowski Lesli A. , Paweletz Cloud P. , Eltoukhy Helmy , Lanman Richard B. , Chudova Darya I. , Talasaz AmirAli
Published: April 2023

Discordant results between Digital Sequencing and clinical ddPCR. Details of the cases discordant between DS and Dana-Farber Clinical Laboratory's ddPCR results with orthogonal follow-up data. *Note, while approved specifically for T790M+ NSCLC, osimertinib has been reported to have clinical activity in T790-wild type patients as well; however, osimertinib efficacy in T790M-wild type patients resistant to 1st generation EGFR TKIs is unclear.
Figure S5 from Validation of a Plasma-Based Comprehensive Cancer Genotyping Assay Utilizing Orthogonal Tissue- and Plasma-Based Methodologies
Authors: Odegaard Justin I. , Vincent John J. , Mortimer Stefanie , Vowles James V. , Ulrich Bryan C. , Banks Kimberly C. , Fairclough Stephen R. , Zill Oliver A. , Sikora Marcin , Mokhtari Reza , Abdueva Diana , Nagy Rebecca J. , Lee Christine E. , Kiedrowski Lesli A. , Paweletz Cloud P. , Eltoukhy Helmy , Lanman Richard B. , Chudova Darya I. , Talasaz AmirAli
Published: April 2023

Per-sample mutation burden distribution by tumor type. Per-sample adjusted mutation count relative to other samples within clinical indication. Green bars indicate the 95th percentile.
Figure S4 from Validation of a Plasma-Based Comprehensive Cancer Genotyping Assay Utilizing Orthogonal Tissue- and Plasma-Based Methodologies
Authors: Odegaard Justin I. , Vincent John J. , Mortimer Stefanie , Vowles James V. , Ulrich Bryan C. , Banks Kimberly C. , Fairclough Stephen R. , Zill Oliver A. , Sikora Marcin , Mokhtari Reza , Abdueva Diana , Nagy Rebecca J. , Lee Christine E. , Kiedrowski Lesli A. , Paweletz Cloud P. , Eltoukhy Helmy , Lanman Richard B. , Chudova Darya I. , Talasaz AmirAli
Published: April 2023

Quantitative precision of Digital Sequencing results. (a) SNV VAFs in 375 consecutive SNV control runs. (b) Indel and fusion VAFs (left y-axis) and CNA copy number (right y-axis) in consecutive CFI control runs. (c) Variation distribution of DS results in 375 consecutive analyses of a single SNV control lot (blue) and multiple consecutive lots of indel (red), fusion (grey), and CNA (orange) controls.
Supplementary Materials, Methods and Supplementary Figure Legends from CKLF1 Enhances Inflammation-Mediated Carcinogenesis and Prevents Doxorubicin-Induced Apoptosis via IL6/STAT3 Signaling in HCC
Authors: Liu Youyi , Liu Lijuan , Zhou Yan , Zhou Ping , Yan Qiujin , Chen Xiaobei , Ding Shuang , Zhu Fan
Published: April 2023

Supplementary materials, methods and supplementary figure legends.
Supplementary Fiuger 1 from CKLF1 Enhances Inflammation-Mediated Carcinogenesis and Prevents Doxorubicin-Induced Apoptosis via IL6/STAT3 Signaling in HCC
Authors: Liu Youyi , Liu Lijuan , Zhou Yan , Zhou Ping , Yan Qiujin , Chen Xiaobei , Ding Shuang , Zhu Fan
Published: April 2023

CKLF1 is highly expressed in HCC tissues and cell lines.
Figure S6 from Copper Chelation as Targeted Therapy in a Mouse Model of Oncogenic BRAF-Driven Papillary Thyroid Cancer
Authors: Xu MengMeng , Casio Michael , Range Danielle E. , Sosa Julie A. , Counter Christopher M.
Published: April 2023

Reduction in MAPK signaling of BCPAP cells treated with vemurafenib and TM.
Table S5 from Functions and Mechanisms of Tumor Necrosis Factor-α and Noncoding RNAs in Bone-Invasive Pituitary Adenomas
Authors: Zhu Haibo , Guo Jing , Shen Yutao , Dong Wei , Gao Hua , Miao Yazhou , Li Chuzhong , Zhang Yazhuo
Published: April 2023

Statistical analysis of related variables between BIPA and NBIPA
Table S4 from Functions and Mechanisms of Tumor Necrosis Factor-α and Noncoding RNAs in Bone-Invasive Pituitary Adenomas
Authors: Zhu Haibo , Guo Jing , Shen Yutao , Dong Wei , Gao Hua , Miao Yazhou , Li Chuzhong , Zhang Yazhuo
Published: April 2023

Clinical information of 274 patients with pituitary adenoma
Supplementary Table S6. from Therapeutic Targeting of TFE3/IRS-1/PI3K/mTOR Axis in Translocation Renal Cell Carcinoma
Authors: Damayanti Nur P. , Budka Justin A. , Khella Heba W.Z , Ferris Mary W. , Ku Sheng Yu , Kauffman Eric , Wood Anthony C. , Ahmed Khunsha , Chintala Venkata Nithinsai , Adelaiye-Ogala Remi , Elbanna May , Orillion Ashley , Chintala Sreenivasulu , Kao Chinghai , Linehan W. Marston , Yousef George M. , Hollenhorst Peter C. , Pili Roberto
Published: April 2023

Lists of statistically enriched pathways targeted by differential expression of miRNA in cluster 3.